Business
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
SHANGHAI, China & JERSEY CITY, N.J., March 28, 2025--Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
About this update from Organon & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2100,"height":315,"url":"https://media.zenfs.com/en/business-wire.com/9bd4501c3a0f907893f66451fe400946"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zOSZusOn2WQTMfBLRaYE.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9bd4501c3a0f907893f66451fe400946","width":960,"height":144},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/DJq3Qto8s3TO9AzF45Qstg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9bd4501c3a0f907893f66451fe400946","width":1200,"height":180}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":401,"height":290,"url":"https://media.zenfs.com/en/business-wire.com/dc6986cbb0fcd03b451a26f8ccb569c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/brk6BL68XyDx14Kwpx7MSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUxMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/dc6986cbb0fcd03b451a26f8ccb569c8","width":401,"height":290}}},{"type":"text","content":"SHANGHAI, China & JERSEY CITY, N.J., March 28, 2025--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, and adjuvant treatment for certain HER2-positive early breast cancer, among other indications.","length":651,"tagName":"p"},{"type":"text","content":"The submission was based on a multicenter, randomized, double-blind, parallel-controlled phase 3 clinical study (NCT05346224) aimed to compare the efficacy and safety of HLX11 with reference Perjeta® (pertuzumab) as a neoadjuvant therapy in patients with HER2-positive, HR-negative early-stage, or locally advanced breast cancer as part of a complete treatment regimen. HLX11 met the primary endpoint, which was the total path...